Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

NCCN Recommends Regorafenib Dose Escalation in Metastatic CRC

March 16th 2018

The NCCN has updated its colorectal cancer (CRC) guidelines, recommending a weekly regorafenib dose-escalation strategy beginning at 80 mg and ending at 160 mg for previously treated patients with metastatic CRC.

Dr. Atreya on How the NCCN Guidelines Have Impacted Treatment Options in mCRC

March 14th 2018

Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the molecular subgroups in metastatic colorectal cancer (mCRC) and viable treatment options for patients with microsatellite instability (MSI)-high and BRAF-mutated cancers.

Dr. Venook Discusses Adjuvant Chemotherapy Duration in CRC

March 7th 2018

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses adjuvant chemotherapy duration in colon cancer.

Nut Consumption Linked to Survival Benefit in Colon Cancer

March 3rd 2018

Patients with stage III colon cancer who ate at least 2 servings of nuts per week had superior disease-free survival and overall survival.

Nut consumption may aid colon cancer survival

March 1st 2018

People with stage III colon cancer who regularly eat nuts are at significantly lower risk of cancer recurrence and mortality than those who don

First Liver Transplant Surgery Performed in Patient With CRC Metastases

February 28th 2018

Although the standard-of-care treatment for patients with liver metastases developing from colorectal cancer is liver resection, only one-third of these patients are candidates for surgery.

Dr. Morse Reflects on Recent Data in Advanced CRC

February 27th 2018

Michael A. Morse, MD, professor, Medicine, Department of Surgery, Duke University School of Medicine, Duke Cancer Institute, reflects on recent data in advanced colorectal cancer.

Improving Outcomes in CRC

February 26th 2018

Progress in CRC Precision Medicine

February 26th 2018

Emerging Immunotherapy Combinations in MSS CRC

February 26th 2018

Managing Toxicities With Immunotherapy in CRC

February 26th 2018

Dosing and Side Effect Management in Metastatic CRC

February 26th 2018

Third-Line Treatment in Refractory CRC

February 26th 2018

Immunotherapy Options in Refractory CRC

February 26th 2018

Supportive Care in Metastatic CRC

February 26th 2018

Maintenance and Second-Line Decisions in CRC

February 26th 2018

Frontline Antibody Selection in Metastatic CRC

February 26th 2018

Left- Versus Right-Sided Tumors in CRC

February 26th 2018

Importance of HER2 Expression in CRC

February 26th 2018

Role of Molecular Testing in CRC Management

February 26th 2018